Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, FVT

Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference


CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference, taking place August 9-10, 2022.

Presentation Details:
Event: Wedbush PacGrow Healthcare Conference
Date / Time: Wednesday, August 10th, 2022, at 10:20am ET
Format: Panel Discussion

A live webcast will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentation.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Theseus management team should contact their Wedbush representative.

About Theseus Pharmaceuticals, Inc.

Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
[email protected]

Investor Contact
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
[email protected]

Josh Rappaport
Stern Investor Relations
212-362-1200
[email protected]

SOURCE Theseus Pharmaceuticals


These press releases may also interest you

at 19:35
Fobi AI Announces Amendment to Asset Purchase Agreement with Wallet Communications SL
Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that, further to its press release dated October 18, 2023, it has...

at 19:00
Autohome Inc. to Hold Annual General Meeting on June 21, 2024
Autohome Inc. ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that it will hold its annual general meeting of shareholders (the "AGM") at 18th Floor Tower B, CEC Plaza, 3 Dan Ling...

at 19:00
Avid Controls Ensures Continuous Support for the Entire GEPC/Converteam MV3000 Product Line
Avid Controls is an authorized licensed manufacturer of the GEPC/Converteam MV3000 product line, and is dedicated to providing world-class support to customers for the entire lifespan of their equipment. The MV3000 modules provide reliable ancillary...

at 18:36
MikeWorldWide Bolsters Digital Strategy Team with Promotions, New Leadership
MikeWorldWide, a leading New York-based, independent public relations agencies with offices across the US and UK has promoted Megan Hueter to lead digital practice and created two new vice president positions to strengthen functional expertise in...

at 18:30
TechTarget's Enterprise Strategy Group Adds Industry Veteran Jim Frey to Lead Networking Coverage, Research and Analysis
TechTarget's Enterprise Strategy Group, a leading IT analyst, research, and strategy firm, today announced the addition of Jim Frey as Principal Analyst to lead the firm's coverage of the networking market. Frey will be covering networking and...

at 18:03
Ferrovial and DXC Technology to drive Generative AI in collaboration with Microsoft
Ferrovial has teamed up with U.S. technology consulting firm DXC Technology to jointly develop the platform known as Quercus to accelerate and scale the adoption of Generative Artificial Intelligence (AI) across the infrastructure company's...

More news about Science and technology...


News published on and distributed by: